DnB Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

DnB Asset Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,184	Closed	-$249K	–	1282
2026 Q1	$249K	Buy	+6,184	New	+$133K	﹤0.01%	1052
2025 Q1	–	Sell	-8,853	Closed	-$282K	–	743
2024 Q4	$282K	Sell	8,853 -75	-0.8%	-$2.25K	﹤0.01%	692
2024 Q3	$257K	Buy	8,928 +956	+12%	+$35.4K	﹤0.01%	689
2024 Q2	$306K	Buy	7,972 +1,904	+31%	+$86.2K	﹤0.01%	674
2024 Q1	$357K	Buy	+6,068	New	+$387K	﹤0.01%	669
2021 Q1	–	Sell	-36,913	Closed	-$2.11M	–	635
2020 Q4	$2.11M	Buy	+36,913	New	+$1.56M	0.02%	452

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

DnB Asset Management's APLS Position: Q2 2026 in Review

DnB Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 6,184 shares — an estimated $249K sold.

DnB Asset Management first reported a position in APLS in Q4 2020 and held it in 6 quarters. The position peaked at $2.11M in Q4 2020. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

DnB Asset Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
DnB Asset Management sold 6,184 Apellis Pharmaceuticals shares in Q2 2026, an estimated $249K.
DnB Asset Management first reported a position in Apellis Pharmaceuticals in Q4 2020 and held it in 6 quarters.
DnB Asset Management's Apellis Pharmaceuticals position peaked at $2.11M in Q4 2020.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.